Table 6

Multivariate analysis

A. Multivariate analysis for PFSa of 72 advanced NSCLC patients
VariablesCategoryRisk ratio95% CIP
HistologySq vs. non-sq1.010.51–2.020.96
StageIIIB vs. IV1.981.02–3.850.042
PS0 vs. 12.361.00–5.610.049
Pgp(−) vs. (+)0.660.36–1.210.18
MRP1(−) vs. (+)0.720.35–1.470.37
MRP2(−) vs. (+)0.700.33–1.470.35
MRP3(−) vs. (+)0.660.30–1.420.29
BCRP(−) vs. (+)2.851.48–5.500.001
B. Multivariate analysis for overall survival of 72 advanced NSCLC patients
VariablesCategoryRisk ratio95% CIP
HistologySq vs. non-sq0.850.38–1.890.70
StageIIIB vs. IV1.820.83–3.970.13
PS0 vs. 12.090.62–7.090.23
Pgp(−) vs. (+)0.850.42–1.690.64
MRP1(−) vs. (+)0.920.38–2.190.85
MRP2(−) vs. (+)1.410.62–3.210.40
MRP3(−) vs. (+)0.970.40–2.300.94
BCRP(−) vs. (+)1.830.91–3.690.08
  • a PFS, progression-free survival; Sq, squamous; NSCLC, non-small cell lung cancer; Pgp, P-glycoprotein; PS, performance status; MRP, multidrug resistance protein; BCRP, breast cancer resistance protein; CI, confidence interval.